The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
Effects of mTOR Inhibition in malignant mesothelioma Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
Dissecting the mTOR pathway in malignant pleural mesothelioma Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
The proteasome inhibitor bortezomib is effective against experimental malignant pleural effusion Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008
mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma Source: Eur Respir J, 51 (5) 1701610; 10.1183/13993003.01610-2017 Year: 2018
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020
ADAM10 membrane-bound protease mediates malignant pleural mesothelioma invasiveness Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management Year: 2018
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions Source: ERJ Open Res, 5 (1) 00016-2019; 10.1183/23120541.00016-2019 Year: 2019
Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells Source: Eur Respir J 2005; 26: Suppl. 49, 225s Year: 2005
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017
Kinase inhibitors Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012
All-trans -retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010